Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5541-5553

  Arita, Minetaro ^a   Wakita, Takaji ^a   Shimizu, Hiroyuki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; SMALL INTERFERING RNA; VALOSIN CONTAINING PROTEIN; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; MUTATION; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RNA REPLICATION; VIRUS REPLICATION;

ADENOSINE TRIPHOSPHATASES; CELL CYCLE PROTEINS; CELL LINE; HUMANS; POLIOMYELITIS; POLIOVIRUS; PROTEIN TRANSPORT; SECRETORY PATHWAY; VIRAL PROTEINS; VIRUS REPLICATION;

AICHI VIRUS; COXSACKIEVIRUS; ENTEROVIRUS; POLIOVIRUS;

EID: 84861306239     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00114-12     Document Type: Article

References (97)

1. Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 82:1787-1797.
2. Arita M, Horie H, Arita M, Nomoto A. 1999. Interaction of poliovirus with its receptor affords a high level of infectivity to the virion in poliovirus infections mediated by the Fc receptor. J. Virol. 73:1066-1074.
3. Arita M, et al. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85:2364-2372.
4. Arita M, Nagata N, Sata T, Miyamura T, Shimizu H. 2006. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 87:3317-3327.
5. Arita M, Takebe Y, Wakita T, Shimizu H. 2010. A bifunctional antienterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J. Gen. Virol. 91:2734-2744.
6. Arita M, Wakita T, Shimizu H. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90:1869-1879.
7. Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 89:2518-2530.
8. Arita M, et al. 2005. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J. Virol. 79:12650-12657.
9. Barnard DL. 2006. Current status of anti-picornavirus therapies. Curr. Pharm. Des. 12:1379-1390.
10. Barton DJ, Flanegan JB. 1997. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidineinhibited activity of protein 2C. J. Virol. 71:8482-8489.
11. Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4:e1000216.
12. Belov GA, Habbersett C, Franco D, Ehrenfeld E. 2007. Activation of cellular Arf GTPases by poliovirus protein 3CD correlates with virus replication. J. Virol. 81:9259-9267.
13. Belov GA, Kovtunovych G, Jackson CL, Ehrenfeld E. 2010. Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1. Cell. Microbiol. 12:1463-1479.
14. Berger KL, et al. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitisCvirus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582.
15. Berstein HD, Baltimore D. 1988. Poliovirus mutant that contains a coldsensitive defect in viral RNA synthesis. J. Virol. 62:2922-2928.
16. Bienz K, Egger D, Troxler M, Pasamontes L. 1990. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J. Virol. 64:1156-1163.
17. Bodian D. 1949. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 6:563-578.
18. Brown-Augsburger P, et al. 1999. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch. Virol. 144:1569-1585.
19. Burgon TB, Jenkins JA, Deitz SB, Spagnolo JF, Kirkegaard K. 2009. Bypass suppression of small-plaque phenotypes by a mutation in poliovirus 2A that enhances apoptosis. J. Virol. 83:10129-10139.
20. Caliguiri LA, Tamm I. 1968. Action of guanidine on the replication of poliovirus RNA. Virology 35:408-417.
21. Chen TC, et al. 2008. Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 62:1169-1173.
22. Cherry S, et al. 2006. COPI activity coupled with fatty acid biosynthesis is required for viral replication. PLoS Pathog. 2:e102.
23. Choe SS, Dodd DA, Kirkegaard K. 2005. Inhibition of cellular protein secretion by picornaviral 3A proteins. Virology 337:18-29.
24. Collett MS, Neyts J, Modlin JF. 2008. A case for developing antiviral drugs against polio. Antiviral Res. 79:179-187.
25. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication, National Research Council. 2006. Exploring the role of antiviral drugs in the eradication of polio: workshop report. National Academies Press, Washington, DC.
26. Couderc T, et al. 1989. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J. Gen. Virol. 70:2907-2918.
27. Cuconati A, Molla A, Wimmer E. 1998. Brefeldin A inhibits cell-free, de novo synthesis of poliovirus. J. Virol. 72:6456-6464.
28. Dalal S, Rosser MF, Cyr DM, Hanson PI. 2004. Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. Mol. Biol. Cell 15: 637-648.
29. Datta U, Dasgupta A. 1994. Expression and subcellular localization of poliovirus VPg-precursor protein 3AB in eukaryotic cells: evidence for glycosylation in vitro. J. Virol. 68:4468-4477.
30. De Palma AM, et al. 2008. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J. Virol. 82:4720-4730.
31. De Palma AM, et al. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857.
32. Dodd DA, Giddings TH, Jr, Kirkegaard K. 2001. Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection. J. Virol. 75:8158-8165.
33. Doedens Jr, Giddings TH, Jr, Kirkegaard K. 1997. Inhibition of endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: genetic and ultrastructural analysis. J. Virol. 71:9054-9064.
34. Doedens JR, Kirkegaard K. 1995. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J. 14:894-907.
35. Eggers HJ, Tamm I. 1961. Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole. J. Exp. Med. 113:657-682.
36. Goueslain L, et al. 2010. Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J. Virol. 84:773-787.
37. Greninger AL, Knudsen GM, Betegon M, Burlingame AL, Derisi JL. 18 January 2012. The 3A protein from multiple picornaviruses utilizes the Golgi adaptor protein ACBD3 to recruit PI4KIIIß. J. Virol. 86:3605-3616.
38. Halawani D, et al. 2009. Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/ VCP ATPase activity and D2 ring conformation. Mol. Cell. Biol. 29:4484-4494.
39. Heath CM, Windsor M, Wileman T. 2001. Aggresomes resemble sites specialized for virus assembly. J. Cell Biol. 153:449-455.
40. Heinz BA, Vance LM. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69:4189-4197.
41. Hetzer M, et al. 2001. Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear assembly. Nat. Cell Biol. 3:1086-1091.
42. Hirabayashi M, et al. 2001. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ. 8:977-984.
43. Hsu NY, et al. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
44. Irurzun A, Perez L, Carrasco L. 1992. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166-175.
45. Ishigaki S, et al. 2004. Physical and functional interaction between Dorfin and Valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders. J. Biol. Chem. 279:51376-51385.
46. Ishikawa K, Sasaki J, Taniguchi K. 2010. Overall linkage map of the nonstructural proteins of Aichi virus. Virus Res. 147:77-84.
47. Ishitsuka H, Ohsawa C, Ohiwa T, Umeda I, Suhara Y. 1982. Antipicornavirus flavone Ro 09-0179. Antimicrob. Agents Chemother. 22:611-616.
48. Jackson WT, et al. 2005. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol. 3:e156.
49. Johnston JA, Ward CL, Kopito RR. 1998. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143:1883-1898.
50. Ju JS, et al. 2009. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J. Cell Biol. 187:875-888.
51. Ju JS, Miller SE, Hanson PI, Weihl CC. 2008. Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J. Biol. Chem. 283:30289-30299.
52. Ju JS, Weihl CC. 2010. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy 6:283-285.
53. Kitami MI, et al. 2006. Dominant-negative effect of mutant valosincontaining protein in aggresome formation. FEBS Lett. 580:474-478.
54. Kobayashi T, Manno A, Kakizuka A. 2007. Involvement of valosincontaining protein (VCP)/p97 in the formation and clearance of abnormal protein aggregates. Genes Cells 12:889-901.
55. Kobayashi T, Tanaka K, Inoue K, Kakizuka A. 2002. Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells. J. Biol. Chem. 277:47358-47365.
56. Koller KJ, Brownstein MJ. 1987. Use of a cDNA clone to identify a supposed precursor protein containing valosin. Nature 325:542-545.
57. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
58. Liu Y, Shevchenko A, Berk AJ. 2005. Adenovirus exploits the cellular aggresome response to accelerate inactivation of the MRN complex. J. Virol. 79:14004-14016.
59. Manno A, Noguchi M, Fukushi J, Motohashi Y, Kakizuka A. 2010. Enhanced ATPase activities as a primary defect of mutant valosincontaining proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Genes Cells 15:911-922.
60. Maynell LA, Kirkegaard K, Klymkowsky MW. 1992. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66:1985-1994.
61. Mizuno Y, Hori S, Kakizuka A, Okamoto K. 2003. Vacuole-creating protein in neurodegenerative diseases in humans. Neurosci. Lett. 343: 77-80.
62. Moffat K, et al. 2005. Effects of foot-and-mouth disease virus nonstructural proteins on the structure and function of the early secretory pathway: 2BC but not 3A blocks endoplasmic reticulum-to-Golgi transport. J. Virol. 79:4382-4395.
63. Nagashima S, Sasaki J, Taniguchi K. 2003. Functional analysis of the stem-loop structures at the 5= end of the Aichi virus genome. Virology 313:56-65.
64. Nowis D, McConnell E, Wojcik C. 2006. Destabilization of the VCPUfd1-Npl4 complex is associated with decreased levels of ERAD substrates. Exp. Cell Res. 312:2921-2932.
65. Peters JM, Walsh MJ, Franke WW. 1990. An abundant and ubiquitous homo-oligomeric ring-shaped ATPase particle related to the putative vesicle fusion proteins Sec18p and NSF. EMBO J. 9:1757-1767.
66. Peyroche A, et al. 1999. Brefeldin A acts to stabilize an abortive ARFGDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. Mol. Cell 3:275-285.
67. Pierini R, Cottam E, Roberts R, Wileman T. 2009. Modulation of membrane traffic between endoplasmic reticulum, ERGIC and Golgi to generate compartments for the replication of bacteria and viruses. Semin. Cell Dev. Biol. 20:828-833.
68. Rabouille C, Levine TP, Peters JM, Warren G. 1995. An NSF-like ATPase, p97, and NSF mediate cisternal regrowth from mitotic Golgi fragments. Cell 82:905-914.
69. Ramadan K, et al. 2007. Cdc48/p97 promotes reformation of the nucleus by extracting the kinase Aurora B from chromatin. Nature 450:1258-1262.
70. Rotbart HA. 2002. Treatment of picornavirus infections. Antiviral Res. 53:83-98.
71. Roy L, et al. 2000. Role of p97 and syntaxin 5 in the assembly of transitional endoplasmic reticulum. Mol. Biol. Cell 11:2529-2542.
72. Sabin AB. 1965. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194:872-876.
73. Salk JE, et al. 1954. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am. J. Public Health Nations Health 44:994-1009.
74. Sandoval IV, Carrasco L. 1997. Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J. Virol. 71:4679-4693.
75. Sasaki J, Ishikawa K, Arita M, Taniguchi K. 2012. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J. 31:754-766.
76. Schroder R, et al. 2005. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann. Neurol. 57:457-461.
77. Shimizu H, et al. 2000. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74:4146-4154.
78. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. 2003. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:834-839.
79. Soderberg O, et al. 2006. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3:995-1000.
80. Sohda M, et al. 2001. Identification and characterization of a novel Golgi protein, GCP60, that interacts with the integral membrane protein giantin. J. Biol. Chem. 276:45298-45306.
81. Strauss DM, Glustrom LW, Wuttke DS. 2003. Towards an understanding of the poliovirus replication complex: the solution structure of the soluble domain of the poliovirus 3A protein. J. Mol. Biol. 330:225-234.
82. Suhy DA, Giddings TH, Jr, Kirkegaard K. 2000. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J. Virol. 74:8953-8965.
83. Tang WF, et al. 2007. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J. Biol. Chem. 282:5888-5898.
84. Taylor MP, Burgon TB, Kirkegaard K, Jackson WT. 2009. Role of microtubules in extracellular release of poliovirus. J. Virol. 83:6599-6609.
85. Teterina NL, et al. 2006. Evidence for functional protein interactions required for poliovirus RNA replication. J. Virol. 80:5327-5337.
86. Teterina NL, Pinto Y, Weaver JD, Jensen KS, Ehrenfeld E. 2011. Analysis of poliovirus protein 3A interactions with viral and cellular proteins in infected cells. J. Virol. 85:4284-4296.
87. Tresse E, et al. 2010. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy 6:217-227.
88. Watts GD, et al. 2004. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosincontaining protein. Nat. Genet. 36:377-381.
89. Weihl CC, Dalal S, Pestronk A, Hanson PI. 2006. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum. Mol. Genet. 15:189-199.
90. Weihl CC, Miller SE, Hanson PI, Pestronk A. 2007. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum. Mol. Genet. 16:919-928.
91. Wessels E, et al. 2006. A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev. Cell 11:191-201.
92. White SR, Lauring B. 2007. AAA+ ATPases: achieving diversity of function with conserved machinery. Traffic 8:1657-1667.
93. Wikel JH, et al. 1980. Synthesis of syn and anti isomers of 6-[[(hydroxyimino) phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J. Med. Chem. 23:368-372.
94. Wileman T. 2006. Aggresomes and autophagy generate sites for virus replication. Science 312:875-878.
95. Wojcik C, et al. 2006. Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells. Mol. Biol. Cell 17:4606-4618.
96. Wojcik C, Yano M, DeMartino GN. 2004. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J. Cell Sci. 117: 281-292.
97. Yamashita T, et al. 1998. Complete nucleotide sequence and genetic organization of Aichi virus, a distinct member of the Picornaviridae associated with acute gastroenteritis in humans. J. Virol. 72:8408-8412.